Published in final edited form as:

Genet Med. 2011 December ; 13(12): 1045–1050. doi:10.1097/GIM.0b013e31822a8113.

Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling

Grace Wang, PhD, MPH^{*} [Postdoctoral Fellow],

Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)
Department of Clinical Pharmacy, School of Pharmacy University of California, San Francisco
3333 California St. Suite 420 San Francisco, CA 94118

Mary S. Beattie, MD, MAS [Associate Clinical Professor],

Department of Medicine University of California, San Francisco Box 1753, San Francisco, CA
94143-1752 Mary.Beattie@ucsfmedctr.org

Ninez A Ponce, MPP, PhD [Associate Professor], and

Department of Health Services School of Public Health University of California, Los Angeles Box
951772, Los Angeles, CA 90095-1772 nponce@ucla.edu

Kathryn A Phillips, PhD [Professor]

Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)
Department of Clinical Pharmacy, School of Pharmacy University of California, San Francisco
3333 California St. Suite 420 San Francisco, CA 94118 phillipsk@pharmacy.ucsf.edu

Abstract

Purpose—Coverage policies for genetic services for hereditary cancers are of interest because the services influence cancer risk reduction for both persons with cancer as well as their family members. We compared coverage policies for BRCA genetic testing and genetic counseling among selected payers in the US to illuminate eligibility criteria variation that may explain differential access by insurance type. We compared these policies to policies for breast cancer screening with MRI to consider whether payers apply a unique policy approach to genetic services.

Methods—We conducted a case study of large private and public payers selected on number of covered lives. We examined coverage policies for BRCA genetic testing, genetic counseling, and screening with MRI and the eligibility criteria for each. We compared eligibility criteria against National Comprehensive Cancer Network guidelines.

Results—Eligibility criteria for BRCA testing were related to personal history and family history of cancer. Although private payers covered BRCA testing for persons with and without cancer, the local Medicare carrier in our study only covered testing for persons with cancer. In contrast,

^{*} author for correspondences (phone) 415-502-7593 (fax) 415-502-0792 wangg@pharmacy.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Arizona's Medicaid program did not cover BRCA testing at all. Few payers had detailed eligibility criteria for genetic counseling. Private payers have more detailed coverage policies for both genetic services and screening with MRI in comparison to public payers.

Conclusion—Despite clinical guidelines establishing standards for BRCA testing, we found differences in coverage policies particularly between private and public payers. Future research and policy discussions can consider how differences in private and public payer policies influence access to genetic technologies and health outcomes.

Keywords

BRCA testing; coverage policy; family history; genetic counseling; hereditary breast and ovarian cancer; payer

INTRODUCTION

BRCA testing is one of the first genetic tests to move from bench to bedside. Several professional associations have included BRCA testing in clinical guidelines to identify patients at high risk for hereditary breast and ovarian cancer.¹⁻⁵ Guidelines from the US Preventive Services Task Force (USPSTF) recommend genetic counseling and BRCA testing for “...women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes.”² In addition, the National Comprehensive Cancer Network (NCCN) lays out in detail a clinical pathway to help providers identify persons with hereditary breast and ovarian cancer.⁴ NCCN has also incorporated into its guidelines American Cancer Society recommendations for breast cancer screening using magnetic resonance imaging (MRI) for persons at high risk for breast cancer.⁶ (Table 1)

Access to BRCA testing and related services often depends on cost and coverage of services by payers.⁷⁻⁹ To leverage value of technologies and services, payers define scope of healthcare benefits based on eligibility criteria. Previous researchers have discussed coverage policy development and have even discussed policy formulation and considerations for genetic testing specifically.¹⁰⁻¹⁵ Although researchers have described policy development processes, few studies have examined the coverage policies themselves. Recently, Latchaw et al reviewed policies of ten private payers in Illinois and observed wide variability in coverage.¹⁶

Coverage policies “...influence[s] the types of medical care Americans receive, because health insurance coverage is the gateway to the availability of medical innovations.”¹⁷ Policies contribute to setting thresholds of whom to test, then which screening and prevention services to offer and when. Without an understanding of the composition and content of the policies, we cannot begin to hypothesize how criteria within the policies may affect access by covered populations or differences in access between payers. Coverage policies for genetic services for hereditary cancers are of particular interest because the services influence cancer risk reduction for both persons with cancer as well as their family members.

We build upon prior research by studying several national and local coverage policies for public and private payers to determine and compare the criteria included in coverage policies for BRCA genetic testing and genetic counseling. We also assess policies for a comparison service, breast cancer screening with MRI, to consider whether payers apply a unique policy approach to genetic testing and genetic counseling in relation to other services. This paper: 1) describes the eligibility criteria for cancer risk genetic counseling, BRCA testing, and breast cancer screening with MRI; 2) compares eligibility criteria between payers and between services, and 3) discusses implications of these policies for covered persons.

MATERIALS AND METHODS

We conducted a case study of selected private and public payers. We chose payers and states with the largest number of covered lives because coverage policies would potentially have an impact on a large number of people. Number of covered lives is estimated by the Health Care Delivery Policy Program at Harvard University and the Kaiser Family Foundation.¹⁸⁻²⁰ We selected states with a higher than average number of beneficiaries in 2007 (Medicaid) and 2010 (Medicare) In total we reviewed policies from eight private payers and 17 states.

We searched several online databases in May 2011 in order to identify BRCA genetic testing and genetic counseling coverage policies among the selected payers. These included private payer websites, state Medicaid sites, the Medicare coverage policy database, and other electronic databases such as PubMed, Lexis Nexis legal, and Google.²¹⁻²⁸

We identified BRCA testing and genetic counseling coverage policies for four private payers (Aetna, Cigna, Humana, and UnitedHealthcare) representing over 50 million covered lives. We identified one local Medicare carrier (Washington State) with a policy addressing BRCA testing. We also found statements from 4 Medicaid programs (AZ, CA, IL, NY).²⁹⁻³⁹ (Table 2) We then identified coverage policies for breast cancer screening with MRI among these payers.⁴⁰⁻⁴³

We used the NCCN clinical guidelines as a framework for examining eligibility criteria. We categorized criteria based on personal history of breast or ovarian cancer; family history of breast or ovarian cancer; race/ethnicity; age at diagnosis; BRCA mutation carrier status, family member carries a BRCA mutation, and/or other criteria.

RESULTS

Genetic testing

Personal history of cancer is a primary criterion for coverage among both private and public payers. Private payers, the local Medicare carrier, and California Medicaid combine this criterion with additional secondary criteria such as young age at diagnosis, family history, family history of BRCA carriers, or ethnicity (for example, founder populations of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or other). Two private payers include clauses related to limited family structure or adoption of children.

Family history of breast and ovarian cancer is a primary criterion for coverage eligibility, but only among private payers and California Medicaid. In contrast, Washington State's local Medicare coverage determination indicates that family history without a personal history of cancer is not adequate for Medicare coverage. The policy states, "Screening services, such as pre-symptomatic genetic tests and services, are those used to detect an undiagnosed disease or disease predisposition, and as such are not a Medicare benefit and not covered by Medicare. Similarly, Medicare may not reimburse the costs of tests/examinations that assess the risk for and/or of a condition unless the risk assessment clearly and directly effects the management of the patient..."³⁷

Finally, documents from state Medicaid programs range from decisions of non-coverage to policies without eligibility criteria. Arizona's policy states that "Genetic testing is not covered to determine whether a member carries a hereditary predisposition to cancer or other diseases. Genetic testing is also not covered for members diagnosed with cancer to determine whether their particular cancer is due to a hereditary genetic mutation known to increase the risks of developing that cancer."³¹ Memos, policy manuals, and fee schedules indicate that Illinois and New York Medicaid programs cover BRCA testing, but we did not identify any specific eligibility criteria from these payers.

Genetic counseling

Private payers have coverage policies for genetic counseling, but do not outline in depth the eligibility criteria for receiving this service. All four private payers refer to genetic counseling services in relation to receiving genetic testing or guiding treatment. Medicare in Washington also covers counseling before and after genetic testing. We did not identify policies for genetic counseling for the Medicaid programs in this study. (Table 3)

Breast cancer screening with MRI

Private payers cover breast cancer screening with MRI for persons at high risk for hereditary breast and ovarian cancer. The eligibility criteria within private payer policies largely reflect NCCN guidelines. (Table 4) Although we identified no policies specific to breast cancer screening with MRI for the public payers, Illinois and New York have considered legislation mandating coverage of screening by all insurers within the state.^{44, 45}

DISCUSSION

Our example of BRCA testing and genetic counseling highlights differences in coverage policies between four private and five public payers that may affect access and outcomes, particularly among enrollees with public insurance.

Private payers' policies are similar in content, and include coverage for those with a personal history of cancer or a family history of cancer. In the absence of coverage for genetic counseling, primary care or other providers may have responsibility for taking and documenting family history. This may affect eligibility for coverage of testing as medical providers do not always take reliable family histories.⁴⁶⁻⁵¹ Requirements for documentation of family history may also have an impact on access among persons who cannot obtain

family history due to blocked family communications, dispersed families, or differing concepts of cancer and family relations.⁵²⁻⁵⁴

The local Medicare policy (first implemented in 2007) that we reviewed covers only persons with a personal history of cancer despite USPSTF recommendations to test women with a family history of cancer.^{2, 55} Future studies can document whether BRCA testing coverage changes among public payers in response to passage of the Patient Protection and Affordable Care Act. This new law eliminates cost-sharing for preventive services recommended by the USPSTF.⁵⁶

Several Medicaid programs in our study have policies with no eligibility criteria or consider BRCA testing a non-covered service. It is unclear what lack of defined criteria may mean for persons seeking BRCA testing or genetic counseling in a public payer setting. One possibility is inconsistent coverage determinations that occur on a case-by-case basis. Alternatively, lack of defined criteria may result in a lower threshold that must be met before receiving coverage. These differences may have implications for access among low income persons and for regional variations in utilization.

We compared policies for BRCA testing to policies for screening with MRI. Private payers included detailed eligibility criteria for both BRCA testing and MRI whereas coverage policies from public payers were largely absent. This suggests that private payers may communicate policies and eligibility criteria more explicitly than public payers, and private payers' open approach may not be unique to genetic testing.

The scope of this assessment is limited to only a convenience sample of payers and policies. The large plans in this analysis may have a more developed system for reviewing evidence and updating coverage policies compared to smaller plans. These large payers, however, may act as trendsetters with smaller payers adopting similar policies based on the large payers' evidence reviews and policies. Although we include a limited number of plans, they cover approximately 50 million privately insured lives, 1.5 million lives under a local Medicare carrier, and 18.7 million lives under 4 state Medicaid programs. This research represents the state of coverage in 2011, but policies change over time. As a result, the policies that we identify may not be those used by the payers to determine coverage. Also, importantly, a lack of policy does not equal lack of coverage; furthermore, the presence of a policy is not synonymous with coverage.⁵⁷

This analysis highlights how even an established genetic technology for a hereditary condition continues to manifest in differential coverage policies. Importantly, we suggest open discussions between policy makers, patients, advocates, and researchers regarding the coverage of genetic technologies among public payers in particular. Within a context of severe state budget constraints, we must continue to evaluate the need for genetic testing in tandem with coverage priorities for other important preventive health services that extend access to a broader segment of the population.

In summary, coverage policies among private and public payers vary despite professional guidelines that establish BRCA testing as standard of care. Policies range from BRCA testing as a non-covered service to policies with detailed eligibility criteria emphasizing

personal history and family history of cancer. Future research and policy discussions can consider how policies affect access and utilization of services among privately insured compared to publicly insured populations. In the future, the Patient Protection and Affordable Care Act may affect coverage policies for BRCA testing and genetic counseling among public payers.

Acknowledgments

This project was funded in part by the National Cancer Institute (# P01CA130818); the Avon Foundation and the Bay Area Breast SPORE (NIH 2P50 CA058207); and the UCSF Helen Diller Family Comprehensive Cancer Center.

REFERENCES

- Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. *J Genet Couns*. Jun; 2007 16(3):241–260. [PubMed: 17508274]
- Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. *Ann Intern Med*. Sep 6; 2005 143(5):355–361. [PubMed: 16144894]
- Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol*. Feb 10; 28(5):893–901. [PubMed: 20065170]
- National Comprehensive Cancer Network. [May 12, 2011] Genetic/familial high-risk assessment: breast and ovarian, version 1.. Practice Guidelines. 2011. [<http://www.nccn.org>].
- American College of Medical Genetics Foundation. Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling, and Testing Guidelines. 1998. www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm
- National Comprehensive Cancer Network. [May 12, 2011] Breast Cancer Screening and Diagnosis, version 1.. Practice Guidelines. 2011. [<http://www.nccn.org>].
- Kieran, S.; Loescher, LJ.; Lim, KH. *Genet Test*. Vol. 11. Spring; 2007. The role of financial factors in acceptance of clinical BRCA genetic testing.; p. 101-110.
- Lee SC, Bernhardt BA, Helzlsouer KJ. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. *Cancer*. Mar 15; 2002 94(6):1876–1885. [PubMed: 11920551]
- Velicer CM, Taplin S. Genetic testing for breast cancer: where are health care providers in the decision process? *Genet Med*. Mar-Apr;2001 3(2):112–119. [PubMed: 11280948]
- Burken MI, Wilson KS, Heller K, Pratt VM, Schoonmaker MM, Seifter E. The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing. *Genet Med*. Apr; 2009 11(4):225–231. [PubMed: 19282775]
- Giacomini M, Miller F, O'Brien BJ. Economic considerations for health insurance coverage of emerging genetic tests. *Community Genet*. 2003; 6(2):61–73. [PubMed: 14560066]
- Logue LJ. Genetic testing coverage and reimbursement: a provider's dilemma. *Clin Leadersh Manag Rev*. Nov-Dec;2003 17(6):346–350. [PubMed: 14692079]
- Ramsey SD, Veenstra DL, Garrison LP Jr. et al. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. *Am J Manag Care*. Apr; 2006 12(4):197–202. [PubMed: 16610921]
- Schoonmaker M, Bernhardt B, Holtzman NA. Coverage of new genetic technologies: what matters to insurers? *Am J Hum Genet*. Oct.1996 59(4):A3. [PubMed: 11644831]
- Schoonmaker MM, Bernhardt BA, Holtzman NA. Factors influencing health insurers' decisions to cover new genetic technologies. *Int J Technol Assess Health Care*. 2000; 16(1):178–189. Winter. [PubMed: 10815363]
- Latchaw M, Ormond K, Smith M, Richardson J, Wicklund C. Health insurance coverage of genetic services in Illinois. *Genet Med*. Aug; 2010 12(8):525–531. [PubMed: 20535020]

17. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). Jan-Jun;2004 (Suppl Web Exclusives):W4-284-296. [PubMed: 15451997]
18. Helfner, C. [May 15, 2010] Covered Lives.. The Numbers. 2007. <http://www.hks.harvard.edu/mrcbg/hcdp/numbers.htm>.
19. Kaiser Family Foundation. [May 15, 2010] Total Number of Medicare Beneficiaries. 2008. <http://www.statehealthfacts.org/comparetable.jsp?typ=1&ind=290&cat=6&sub=74&sortc=1&o=a>.
20. Kaiser Family Foundation. [May 15, 2010] Total Medicaid Enrollment, FY2007. 2006. <http://www.statehealthfacts.org/comparetable.jsp?typ=1&ind=198&cat=4&sub=52&sortc=1&o=a>.
21. Aetna. [May 12, 2011] Medical clinical policy bulletins. http://www.aetna.com/healthcare-professionals/policies-guidelines/medical_clinical_policy_bulletins.html.
22. Centers for Medicaid and Medicare Services. [May 12, 2011] Medicare coverage database. <http://www.cms.gov/mcd/search.asp?from2=search.asp&>.
23. Cigna. [May 12, 2011] Coverage Policies/Criteria Medical & Pharmacy Index. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/index.html.
24. Humana. [May 12, 2011] Medical Coverage Policies. http://apps.humana.com/tad/tad_new/home.aspx?type=provider.
25. State of California Department of Health Care Services. [May 12, 2011] Provider Manuals. http://files.medical.ca.gov/pubsdoco/manuals_menu.asp.
26. UnitedHealthcare. [May 12, 2011] Medical & Drug Policies and Coverage Determination Guidelines. <https://www.unitedhealthcareonline.com/b2c/CmaAction.do?channelId=016228193392b010Vg nVCM100000c520720a>.
27. Arizona Health Care Cost Containment System (AHCCCS). [May 12, 2011] AHCCCS Medical Policy Manual (AMPM). <http://www.azahcccs.gov/shared/MedicalPolicyManual/MedicalPolicyManual.aspx>.
28. New York State Department of Health. [May 12, 2011] Provider Manuals. <http://www.emedny.org/providermanuals/index.html>.
29. Aetna. [May 12, 2011] BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy.. Clinical Policy Bulletin. 2010. http://www.aetna.com/cpb/medical/data/200_299/0227.html.
30. Aetna. [May 11, 2011] Genetic Counseling.. Clinical Policy Bulletin. 2010. http://www.aetna.com/cpb/medical/data/100_199/0189.html.
31. Arizona Health Care Cost Containment System (AHCCCS). [May 12, 2011] Medical Policy for AHCCCS Covered Services. Chapter 300 <http://www.azahcccs.gov/shared/Downloads/MedicalPolicyManual/Chap300.pdf>.
32. Cigna. [May 12, 2011] Genetic Testing for Susceptibility to Breast and Ovarian Cancer (e.g., BRCA1 & BRCA2) Cigna Medical Coverage Policy. 2010. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0001_coveragepositioncriteria_genetic_testing_for_breast_and_ovarian_cancer.pdf.
33. Cigna. [May 12, 2011] Genetic Counseling.. Cigna Medical Coverage Policy. 2011. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0297_coveragepositioncriteria_genetic_counseling.pdf.
34. Humana. [May 12, 2011] Genetic Testing and Counseling for Hereditary Cancer Syndromes Medical Coverage Policy. 2011. http://apps.humana.com/tad/tad_new/Search.aspx?criteria=genetic&searchtype=freetext.
35. Illinois Department of Healthcare and Family Services. [May 12, 2011] Reimbursement for Genetic Counseling Services Rendered by Genetic Counselors.. Informational Notice. 2008. <http://www.hfs.illinois.gov/html/101408genetic.html>.
36. New York State Department of Health. [May 12, 2011] Fee schedule.. Laboratory Manual. 2010. <http://www.emedny.org/ProviderManuals/Laboratory/index.html>.
37. Noridian Administrative Services. [May 12, 2011] Genetic Testing.. Local Coverage Determination. 2010. <http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=23664&ContrId=35&ver=29&ContrVer=1&SearchType=Advanced&CoverageSelection=Local&PolicyType=Both&s=56&KeyWord=genetic&KeyWordLookUp=Doc&KeyWordSearchType=Exact&kq=true&bc=IAAABAAAAAA&>.

38. State of California Department of Health Care Services. [May 12, 2011] Pathology: Billing and Modifiers.. Provider Manuals. 2011. http://files.medi-cal.ca.gov/pubsdoco/manuals_menu.asp.
39. UnitedHealthcare. [May 12, 2011] Genetic Testing for Hereditary Breast and/or Ovarian Cancer Syndrome (HBOC).. Medical Policy. 2010. https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/Medical%20Policies/Genetic_Testing_HBOC_Syndrome.pdf.
40. Aetna. [May 12, 2011] Magnetic Resonance Imaging (MRI) of the Breast.. Clinical Policy Bulletin. 2011. http://www.aetna.com/cpb/medical/data/100_199/0105.html.
41. Cigna. [May 12, 2011] Magnetic Resonance Imaging (MRI) of the Breast. 2010. http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0155_coveragepositioncriteria_mri_of_the_breast.pdf.
42. Humana. [May 12, 2011] Breast Magnetic Resonance Imaging (MRI).. Medical Coverage Policy. 2010. http://apps.humana.com/tad/tad_new/Search.aspx?criteria=MRI&searchtype=freetext.
43. UnitedHealthcare. [May 12, 2011] Physician Guidelines: Current, Evidence-based Recommendations Regarding Imaging. 2010. https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Clinician%20Resources/Radiology%20Notification%20Program/Radiology%20Notification%20docs/Evidence_based_Clinical_Guidelines_Imaging.pdf.
44. Illinois General Assembly. [May 12, 2011] Bill Status of SB1464. 94th General Assembly. <http://www.ilga.gov/legislation/billstatus.asp?DocNum=1464&GAID=8&GA=94&DocTypeID=SB&LegID=18737&SessionID=50>.
45. New York State Assembly. [May 12, 2011] A01431 Summary. http://assembly.state.ny.us/leg/?default_fld=&bn=A01431&Summary=Y&Actions=Y&Votes=Y&Memo=Y&Text=Y.
46. Tyler CV Jr, Snyder CW. Cancer risk assessment: examining the family physician's role. J Am Board Fam Med. Sep-Oct;2006 19(5):468–477. [PubMed: 16951296]
47. Sifri RD, Wender R, Paynter N. Cancer risk assessment from family history: gaps in primary care practice. J Fam Pract. Oct.2002 51(10):856. [PubMed: 12836643]
48. Rich EC, Burke W, Heaton CJ, et al. Reconsidering the family history in primary care. J Gen Intern Med. Mar; 2004 19(3):273–280. [PubMed: 15009784]
49. Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med. Dec 15; 2009 151(12):878–885. [PubMed: 19884616]
50. Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med. Dec 15; 2009 151(12):872–877. [PubMed: 19884615]
51. Burke W, Culver J, Pinsky L, et al. Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A. Mar; 2009 149A(3):349–356. [PubMed: 19208375]
52. Chivers Seymour K, Addington-Hall J, Lucassen AM, Foster CL. What Facilitates or Impedes Family Communication Following Genetic Testing for Cancer Risk? A Systematic Review and Meta-Synthesis of Primary Qualitative Research. J Genet Couns. 2010; 19(4):330–342. [PubMed: 20379768]
53. McGrath BB, Edwards KL. When family means more (or less) than genetics: the intersection of culture, family and genomics. J Transcult Nurs. Jul; 2009 20(3):270–277. [PubMed: 19398610]
54. Orom H, Cote ML, Gonzalez HM, Underwood W 3rd, Schwartz AG. Family history of cancer: is it an accurate indicator of cancer risk in the immigrant population? Cancer. Jan 15; 2008 112(2):399–406. [PubMed: 18072272]
55. Lesser LI, Krist AH, Kamerow DB, Bazemore AW. Comparison between US Preventive Services Task Force recommendations and Medicare coverage. Ann Fam Med. Jan-Feb;2011 9(1):44–49. [PubMed: 21242560]
56. Henry, J.; Kaiser Family Foundation. [May 12, 2011] Focus on Health Reform. 2010. <http://www.kff.org/healthreform/upload/8061.pdf>.
57. Huang AJ, Gemperli MP, Bergthold L, Singer SS, Garber A. Health plans' coverage determinations for technology-based interventions: the case of electrical bone growth stimulation. Am J Manag Care. Dec; 2004 10(12):957–962. [PubMed: 15617371]

Table 1

National Comprehensive Cancer Network (NCCN) clinical guidelines

NCCN recommends BRCA testing for the following people:	
Individuals from a family with a known BRCA mutation;	
OR	
Individuals with a personal history of breast cancer and:	
• diagnosed age<=45 y	
• diagnosed age<=50 y with >= 1 close blood relative with breast cancer <= 50 y and/or >= 1 close blood relative with epithelial ovarian/fallopian tube/primary peritoneal cancer at any age	
• two breast primaries when first breast cancer diagnosis occurred prior to age 50	
• diagnosed age < 60 y with a triple negative breast cancer	
• diagnosed age <50 y with a limited family history	
• diagnosed at any age, with >=2 close blood relative with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer at any age	
• close male blood relative with breast cancer	
• personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer	
• ethnicity associated with higher mutation frequency (eg. Ashkenzi Jewish)	
OR	
Individuals with a personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer;	
OR	
Individuals with a personal history of male breast cancer;	
OR	
Individuals with a personal history of breast and/or ovarian cancer at any age with >= 2 close blood relatives with pancreatic cancer at any age	
OR	
Individuals with a personal history of pancreatic cancer at any age with >= 2 close blood relatives with breast and/or ovarian cancer and/or pancreatic cancer at any age	
OR	
Individuals whose family history of cancer reflect:	
• first or second degree blood relative meeting any of the above criteria	
• third degree blood relative with breast cancer and/or ovarian/fallopian tube/primary peritoneal cancer with >= 2 close blood relatives with breast cancer (at least one with breast cancer <= 50 y) and/or ovarian cancer	
NCCN recommends annual breast cancer screening with MRI as an adjunct to mammography for the following people:	
Individuals with a BRCA mutation;	
OR	
First-degree, untested relatives of BRCA carriers;	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

OR
Individuals with a lifetime breast/ovarian cancer risk of 20% or greater as defined by BRCA_{PRO} or other models based on family history; OR
carrier or family history of mutation in TP53 or PTEN;
OR
radiation to the chest between ages 10 and 30 years

Sources:

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2011. Practice Guidelines. <http://www.nccn.org>. Accessed May 12, 2011.

National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis, version 1.2011. Practice Guidelines. <http://www.nccn.org>. Accessed May 12, 2011.

* Eligibility criteria within BRCA testing coverage policies, by payer

Criterion 1	AND criterion 2	AND criterion 3	Private payers				Medicare LCD			Medicaid		
			United	Humana	Aetna	Cigna	WA	AZ	CA	IL	NY	
Personal hx	Age < 45		•	•	•	•	•		•			
	Age < 50			•					•			
		family hx	•	•	•	•						
		limited family or adopted	•		•							
	family hx		•	•	•	•	•		•			
	ethnicity		•	•	•	•	•		•			
	relative		•		•		•					
Family hx			•	•	•	•			•			
	age of relative		•						•			
	ethnicity		•	•					•			
	relative								•			
Relative			•	•	•	•						
Other					risk tool gives 10% probability of mutation		to manage patient; informed consent for post-test counseling; lab meets ASCO recommendations	Non covered service	Covered; no eligibility criteria identified	Covered; necessary information accompanies claims		

* This table describes the layers of criteria within some coverage policies. Criterion 1 represents the broadest category of requirements. Criterion 2 and criterion 3 may be added as additional requirements. For example, United will cover BRCA testing for a person with a personal history of cancer (criterion 1) who was diagnosed before the age of 50 (criterion 2) AND who has a family history of breast/ovarian cancer (criterion 3).

Table 3
Eligibility criteria within coverage policies for genetic counseling for disease risk, by payer

Private payers				Medicaid					
				Medicare LCD					
	United	Humana	Aetna	Cigna	WA	AZ	CA	IL	NY
	Conducted prior to and after genetic testing	Conducted by a physician or certified genetic counselor; clinically valid test is available; test impacts treatment, is for the number of genes to establish diagnosis, is allowed once during lifetime per disease.	Authorized by primary care physician; provided with genetic testing and American College of Medical Genetics guidelines	pre- and post-test genetic counseling with a physician or a licensed or certified genetic counselor for an individual recommended for covered genetic testing	Conducted by a qualified and trained practitioner	No policy identified	No policy identified	Service is covered, but no eligibility criteria were identified	No policy identified

Abbreviations: LCD=local coverage determination

Table 4

Eligibility within coverage policies for breast cancer screening with MRI

Criterion	Private payers				Medicare			Medicaid		
	United	Humana	Aetna	Cigna	WA	AZ	CA	IL	NY	
BRCA+	•	•	•	•	•					
Relative	•	•	•	•						
Model	•	•	•	•						
TP53/PTEN	•	•	•	•						
Radiation	•	•	•	•						
Other	Male relative with breast cancer; Relatives with either 2 breast cancers or breast and ovarian cancer; Two or more first degree relatives with breast cancer; Family history of breast or ovarian cancer and Ashkenazi Jewish background				No policy identified	No policy identified	No policy identified	No policy identified	No policy identified	*

Abbreviations: BRCA+ = Individuals with a BRCA mutation; Relative = First-degree, untested relatives of BRCA carriers; Model = Individuals with a lifetime breast/ovarian cancer risk of 20% or greater as defined by BRCAPRO or other models based on family history; radiation = radiation to the chest between ages 10 and 30 years; TP53/PTEN = carrier or family history of mutation in TP53 or PTEN

* These states have considered legislation mandating coverage of breast cancer screening with MRI. At the time of manuscript preparation, none of the bills had passed.